Metraipolis › archive › dc_e99b7501bb88

Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung… — Europe PMC PMID:41041327

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41041327
DOI
10.3389/fimmu.2025.1613368
License (as archived)
solo-consultazione
Archived
2026-11-09T21:52:27.224Z
SHA-256 of the archived text
de1bfaf70913052dee8456e9c01c3919866f29b210e037f2abb91756ba93bef0
Stable URL of this page
https://metraipolis.com/documento/dc_e99b7501bb88

How to cite

Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung… — Europe PMC PMID:41041327 — Europe PMC (en), https://europepmc.org/article/MED/41041327 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e99b7501bb88 (Metraipolis archive dc_e99b7501bb88, sha256 de1bfaf70913052dee8456e9c01c3919866f29b210e037f2abb91756ba93bef0)
BibTeX
@misc{dce99b7501bb88,
  title = {Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung… — Europe PMC PMID:41041327},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41041327},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e99b7501bb88; sha256 de1bfaf70913052dee8456e9c01c3919866f29b210e037f2abb91756ba93bef0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41041327. Agents can read the archived copy with the MCP tool read_document.